The verdict
Our read at a glance.
Whether bivalirudin's approved procedural anticoagulant role is understood within that specific cardiology setting, rather than generalized.
- The signal
- Randomized trials support bivalirudin as an anticoagulant during percutaneous coronary intervention, comparing its bleeding and ischemic outcomes against heparin-based strategies. It is a useful option in patients who cannot receive heparin.
- The unknown
- How it compares with heparin across different procedural and patient settings, including the balance of bleeding reduction against stent-thrombosis risk.
- Our read
- A procedural anticoagulant for the cath lab, not a general blood thinner you manage at home. Bivalirudin is well studied for use during heart procedures, so its role is specific and hospital-based.
The mechanism
How it works.
Bivalirudin is a synthetic 20-amino-acid peptide that directly binds thrombin, the enzyme that converts fibrinogen into the fibrin mesh of a clot. It clamps onto both the active site and the substrate-binding groove of thrombin at once, blocking it from acting on fibrinogen and platelets, which stops clot formation during procedures such as angioplasty. Thrombin slowly cleaves the bound peptide, so its anticoagulant effect wears off within an hour or so after the infusion stops.
Safety & regulatory boundary
The consequential part.
Bivalirudin is a procedural anticoagulant with bleeding risk, and acute stent thrombosis has been reported in some settings. It is administered in the hospital for a specific cardiology indication. Angiomax and other bivalirudin products are not the same as compounded or research-labeled bivalirudin, and the approved use does not extend to any general or wellness setting.
What's next
What we're watching.
Comparative trial data with heparin, optimal use in different patient populations, and bleeding-versus-thrombosis trade-offs.
Context
Why this is discussed.
Bivalirudin is one of the anticoagulant options used during heart-artery procedures, and it is often compared with heparin.
The evidence base
23 cited references.
Regulatory & labels3
Civica, Inc. (FDA label) · 2025
Dr. Reddy's Laboratories Limited (FDA label) · 2019
Meitheal Pharmaceuticals Inc. (FDA label) · 2024
Registered trials8
ClinicalTrials.gov · PHASE2 · RECRUITING · 2024-05-01
ClinicalTrials.gov · RECRUITING · 2020-03-05
ClinicalTrials.gov · NA · RECRUITING · 2024-06-03
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2026-02-01
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-04-15
ClinicalTrials.gov · NA · RECRUITING · 2025-08-13
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2018-06-29
ClinicalTrials.gov · NA · COMPLETED · 2019-02-14
Indexed literature (PubMed)12
Cuker A et al. · Blood Adv · 2018
McMichael A et al. · Pediatr Crit Care Med · 2025
Hu Y et al. · J Vasc Surg · 2019
Warkentin TE et al. · Expert Opin Pharmacother · 2005
Warkentin TE et al. · Thromb Haemost · 2008
Pötzsch B · Med Klin Intensivmed Notfmed · 2013
Lee CJ et al. · Br J Clin Pharmacol · 2011
Wieruszewski PM et al. · ASAIO J · 2023
Chen J et al. · Pharmacotherapy · 2023
Al-Abdouh A et al. · Cardiovasc Revasc Med · 2024
Olmedo W et al. · Vascular · 2019
De Luca G · Cardiovasc Ther · 2012
Keep reading